One Year After Spike In American Deaths From China-sourced Contaminated Heparin, U.S. Pharmocopeia Issues Revised Standards
This article was originally published in PharmAsia News
Executive Summary
BEIJING - When heparin sourced from China mysteriously and suddenly began triggering a spike in extreme adverse reactions and deaths across American hospitals 18 months ago, U.S. FDA rapidly called on the U.S. Pharmacopeial Convention to help devise new testing methods to determine the purity and quality of the blood thinner